Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of d-usnic acid or combination of d-usnic acid and paclitaxel in preparing drug for treating and resisting lung squamous carcinoma

A technology of D-lichenic acid and squamous cell carcinoma of the lung, which is applied in the field of medicine to achieve the effect of improving the treatment effect

Inactive Publication Date: 2020-02-28
GUANGDONG PHARMA UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether D-lichenic acid is effective for squamous cell carcinoma of the lung has not been reported so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of d-usnic acid or combination of d-usnic acid and paclitaxel in preparing drug for treating and resisting lung squamous carcinoma
  • Application of d-usnic acid or combination of d-usnic acid and paclitaxel in preparing drug for treating and resisting lung squamous carcinoma
  • Application of d-usnic acid or combination of d-usnic acid and paclitaxel in preparing drug for treating and resisting lung squamous carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] In order to allow those skilled in the art to understand the present invention more clearly and intuitively, the present invention will be further described below.

[0020] Materials and methods

[0021] Reagent type

[0022] D-lichenic acid (S2252) was purchased from Selleckchem. TBHQ (HY-B0015, CAS No.: 33069-62-4), LY294002 (PI3K inhibitor) (HY-10108, CAS No.: 154447-36-6) and Paclitaxel (HY-B0015, CAS No.: 33069-62- 4 was purchased from MedChemExpres (MCE). Co, N-acetyl-L-cysteine ​​(NAC) (#A7250, CAS No.: 616-91-1) was purchased from Sigma Chemical Co. All other reagents were purchased from Sigma Chemical Co.

[0023] Cell Lines and Cell Culture

[0024] Human lung squamous cell carcinoma cell lines (H520 and Calu-1)) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were grown in RPMI-1640 medium (GIBCO, Invitrogen, USA) with 10% FBS and incubated in 5% CO 2 and 37°C temperature CO 2 Incubator (Thermo Fisher Scientifi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of d-usnic acid in preparing drug for treating and resisting lung squamous carcinoma and application of a combination of d-usnic acid and paclitaxel in preparing drug for treating and resisting lung squamous carcinoma. Repeated experiments find that the d-usnic acid can reduce lung squamous carcinoma cell survival and can lead to explosive generation of reactiveoxygen species (ROS) by inhibiting mitochondrial respiratory chain and Nrf2 expression so as to remarkably induce lung squamous carcinoma cell apoptosis; combined application of the d-usnic acid andpaclitaxel can synergistically resist lung squamous carcinoma. Naked mouse tumor formation experiments prove effectiveness of the d-usnic acid in resisting lung squamous carcinoma in vivo and synergistic anticancer effect of the combination of the d-usnic acid and paclitaxel. An experiment basis is provided for selection of effective assistant drug for clinically resisting lung squamous carcinoma,and experimental data support to further develop the d-usnic acid which is a drug candidate for resisting lung squamous carcinoma and treatment schemes combining the d-usnic acid with paclitaxel.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of D-lichenic acid alone or in combination with paclitaxel in the preparation of medicines for treating and resisting squamous cell carcinoma of the lung. Background technique [0002] Among various malignant tumors, the morbidity and mortality of lung cancer rank first. The basic types of lung cancer are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which NSCLC accounts for about 80%-85%, and NSCLC is divided into three main types: lung adenocarcinoma, lung squamous cell carcinoma and large cell lung cancer. subtype, of which squamous cell carcinoma of the lung accounts for about 30%. Compared with lung adenocarcinoma, patients with squamous cell carcinoma of the lung have poor response to current clinically used chemotherapy drugs and targeted drugs, and their prognosis is poor. Therefore, there is an urgent need to research and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61K31/337A61P35/00
CPCA61K31/337A61K31/343A61P35/00A61K2300/00
Inventor 刘冰齐婉辰张陆勇
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com